Non-alcoholic steatohepatitis: the therapeutic challenge of a global epidemic

Authors Marialena Mouzaki, Johane Allard.


Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide. Nonalcoholic
steatohepatitis (NASH) reflects severe liver disease within the NAFLD spectrum
and can progress to end-stage liver disease. Within this manuscript we review the available
evidence for the treatment of NASH as well as the newer therapeutic agents that are currently
being investigated.

Keywords NASH, fatty liver, treatment, vitamin E, pioglitazone

Ann Gastroenterol 2012; 25 (2): 207-217

Invited Reviews